5:08 PM
 | 
Jan 18, 2013
 |  BC Extra  |  Top Story

CHMP backs Ilaris for gouty arthritis

EMA's CHMP issued a number of positive opinions on Friday, including a recommendation to expand the label for Ilaris canakinumab from Novartis AG (NYSE:NVS; SIX:NOVN) to include treatment of gouty arthritis. Ilaris is recommended to treat adults with frequent gouty arthritis attacks in whom NSAIDs and colchicine are contraindicated, are not tolerated or do not provide an adequate response, and in whom repeated courses of corticosteroids are not...

Read the full 330 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >